Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Bioness completes initial enrollment phase of Fastest study

Bioness has completed initial enrollment phase of the Fastest study to further examine the affect of its Ness L300 wireless neurostimulation technology.

The Ness L300 provides an electrical stimulus to the muscles of the lower leg in order to help lift the foot up while walking.

The Fastest study is designed to demonstrate the superiority of the Ness L300 Foot Drop System over standard ankle-foot orthosis (AFO) therapy and has enrolled 176 with individuals with foot drop at 11 US centers.

Patients will receive either the Ness L300 or an AFO rehabilitation therapies, and will be followed for six months and evaluated based on gait function, stroke-specific quality of life and safety.

Bioness president Thomas Fogarty said they look forward to see the outcome of this study and further quantifying the impact of this technology for those who need it most.